Company intelligence
Lobe Sciences Ltd.
Building Value from Concept to Clinic
About Lobe Sciences Ltd.
Lobe Sciences Ltd. is a Canadian public biopharmaceutical company focused on advancing high-potential therapeutic assets through disciplined pharmaceutical development. The Company identifies, develops, and de-risks programs addressing unmet medical needs, then partners with established organizations for late-stage development and commercialization. Our shares trade on the Canadian Securities Exchange (CSE: LOBE), OTCQB (LOBEF), and Frankfurt Stock Exchange (FWB: LOBE). Through our majority-owned subsidiaries, Cynaptec Pharmaceuticals and Applied Lipid Technologies (ALT), we advance programs within focused entities designed to isolate risk, align capital, and progress assets independently through clinical development.
Verified activity
Signals from Lobe Sciences Ltd.
4 published signals
Products & Services
Lobe Sciences Ltd. advanced L-130, its differentiated conjugated psilocin therapeutic being developed at non-hallucinogenic doses for chronic cluster headache.
Reported by Lobe Sciences Ltd.
People
Lobe Sciences Ltd. transitioned Mirza Rahimani from CFO to Vice President of Finance.
Reported by Lobe Sciences Ltd.
People
Lobe Sciences Ltd. appointed Dr. David Kideckel, PhD, MBA, as Chief Financial Officer effective September 1, 2026.
Reported by Lobe Sciences Ltd.
Capital & Finance
Lobe Sciences Ltd. closed the second tranche of its non-brokered private placement of common shares at C$0.085 per share, totaling 25,411,762 shares for gross proceeds of C$2.16 million.
Reported by Lobe Sciences Ltd.